Caroline Gaynor

Caroline is a principal with Lightstone Ventures based out of the firm’s Dublin office. She serves as a director or observer on the boards of ALX Oncology, Carrick Therapeutics, Cerevance, and FIRE-1. Prior to Lightstone, Caroline consulted for multiple biopharma and medtech start-ups. Prior to that, she served on the board of senior management for Bayer Ltd. Ireland as head of market access and reimbursement and was responsible for health economics, health technology assessment applications and reimbursement/pricing negotiations for new drugs. Prior to Bayer, Caroline held roles in regulatory affairs, product management, marketing and strategic business development. Caroline holds a BS in Pharmacy from Trinity College Dublin, MS in Pharmaceutical Medicine from Trinity College Dublin, and an MS in BioInnovation from National University of Ireland, Galway.